African Medicines Regulatory Harmonisation (AMRH) Initiative:
Presentation by Margareth Ndomondo-SigondaPharmaceutical Coordinator
NEPAD Agency26 March, 2013
1
Presentation Outline1. Background
2. AMRH Vision, Mission, SD & Partners
3. AMRH achievements
4. Pharma Industry participation• Perceptions by local manufacturers• Opportunities for local manufacturers• Market Viability
5. Conclusion & Way Forward
2
3
1. AMRH Initiative Background
New Partnership for Africa’s Development (NEPAD)
• 2001: A Programme of the African Union (AU) adopted in Lusaka, Zambia
• February 2010: Integration of NEPAD under the AU structures• Re-newed mandate as a technical body of the African Union
to:• Facilitate and coordinate the implementation of the
continental and regional programmes and projects;• Mobilize resources and partners in support of the
implementation of Africa’s priority programmes and projects;
• Conduct and coordinate research and knowledge management;
• Coordinate the implementation of programmes and projects, &
• Advocate on the AU and NEPAD vision, mission and core principles/values
Est.: OAU – May 1963 AU – July 2002Tel: +251-11 551 77 00 Fax: +251-11 551 78 44 Website: www.africa-union.org
Head Office Address: P.O. Box 3243, Roosevelt Street (Old Airport Area), W21K19, Addis Ababa, Ethiopia
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
C/African Rep.
Chad
Comoros
DRC
Congo
Côte d’Ivoire
Djibouti
Egypt
Equatorial Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Libya
Madagascar
Malawi
Mali
Mauritania
Mauritius
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sharawi Arab DR
São Tomé & Prínc.
Senegal
Seychelles
Sierra Leone
Somalia
South Africa
Sudan
Swaziland
Tanzania
Togo
Tunisia
Uganda
Zambia
Zimbabwe
Crea
ted
by:
Mrs
. And
riëtt
e Fe
rrei
ra –
NEP
AD S
ecre
taria
t, 12
58 L
ever
Roa
d, H
eadw
ay
Hill
, Mid
rand
, Joh
anne
sbur
g, S
outh
Afr
ica,
Em
ail:
andr
iett
ef@
nepa
d.or
g In
form
ation
sou
rce:
ww
w.a
fric
a-un
ion.
org
African Union
• 54 member states of the African Union– fifty two republics, and two kingdoms– South Sudan is the newest member state, joining on 2011
July 27
• Total population: ~ 1 billion• 8 Regional Economic Communities:
– Arab Maghreb Union (UMA), Common Market for Eastern and Southern Africa (COMESA), Community of Sahel Saharan States (CEN-SAD), East African Community (EAC), Economic Community of Central African States (ECCAS), Economic Community of West African States (ECOWAS), Intergovernmental Authority on Development (IGAD) and Southern Africa development Community (SADC)
04/12/2023 6
PMPA-AMRH GenesisAfrican Union Assembly Decision 55 of 2005 - Abuja Summit: African Union Commission (AUC) to develop a Pharmaceutical
Manufacturing Plan for Africa (PMPA) within the NEPAD Framework Aim: to contribute to a sustainable supply of quality essential medicines
to improve public health and promote industrial and economic development on the continent
Critical elements for successful implementation of PMPA : Legislative framework: Sound regulatory systems e.g. GMP, GDP, GCP
e.t.c. Full use of TRIPS and related flexibilities Appraisal of technical feasibility and financial viability A market size to ensure sustainability Technology transfer Human resource Duties and taxes
7
2. AMRH Vision, Mission, Strategic Directions & Partners
04/12/2023 8
AMRH VISION & MISSION
VISION:African people have access to essential medical products and technologies
MISSION:Provide leadership in creating an enabling regulatory environment for pharmaceutical sector development in Africa
04/12/2023 9
AMRH Strategic Directions• Policy and Regulatory Reforms
– Increased use of harmonized policies and regulatory frameworks by member states
• Regulatory capacity Development – Increased human and institutional capacity for regulation of
medical products and technologies– Use of existing structures & institutions to ensure sustainability
• Knowledge Management– Knowledge assets on medicines regulation at country, regional
and continental levels created
• Enabling environment for AMRH– Governance & coordination– Partnership Platform Accountability Framework– M&E and impact assessment framework04/12/2023 10
Consortium of key partners established to accelerate and ensure African Medicines Regulatory Harmonization
(AMRH)
11
Consortium and majorstakeholders convened inFebruary and November
2009
Consortium Partners
Other Stakeholders NMRA Representatives
Regional Economic Communities and Organizations (RECs)
COHRED
• Unanimous consensus emerged: now is the right time to push for regulatory harmonization in Africa
• Global Medicines Regulatory Harmonization - Multi-Donor Trust Fund established under the World Bank
AMRH Partners….
AMRH Partners Roles• Mobilising political support, and
financial and technical resources for AMRH programme
• Promoting and facilitating inter-REC communication, coordination, technical consistency and shared learning
• Building a continental initiative, assisting in priority setting and plans for regulatory harmonization
Political/Technical/Operational• New Partnership for Africa’s
Development (NEPAD Agency)• African Union Commission
(AUC)• Pan African Parliament (PAP)• World Health Organization
(WHO)• The World Bank
Donors & NGOs• Bill & Melinda Gates
Foundation• UK Department for
International Development (DFID)
• Clinton Health Access Initiative (CHAI) 12
AMRH…• Overall Objective
– To improve public health by increasing access to quality, safe and efficacious essential medicines for the treatment of priority diseases
– Contribute to socio-economic development agenda for Africa
• Specific Objective– To reduce the time taken to register priority medicines
– Registration as pathfinder to a broader harmonization of other regulatory functions and products
13
AMRH Approach…
Building on the existing regional efforts, political mandates and plan
14
AMRH …
15
Earlier approvalof more
medicines & vaccines
Today
~ 54 National Medicines Regulatory Authorities (NMRAs) governing medicines regulation across Africa
Lack/inadequate medicines policies and laws
Regulators' capacity highly variable: Financial, HR, Institutional
Different requirements and formats, lack of clear guidelines
Minimal transparency, No clear timelines
Reference evaluations1 underleveraged
Streamlined (harmonized)
future
Between 5-7 regional economic communities (RECs)
covering the entire African continent1
Harmonized medicines policies and Laws
Stronger, institutionalized regulatory capacity & systems
strengthening programmes
Single set of requirements, Clear guidelines, Fewer
dossiers to prepare
Transparent regulatory processes with clear timelines
Resource pooling and information sharing1. WHO prequalification, Article 58 positive opinions, stringent regulatory approval, certificate of pharmaceutical product (CPP) 15
Critical Milestones
Member States Operating independently
Member States Collaborate on selected topics
Harmonised standards and broad collaboration
Centralized Procedure
• each country has its own technical requirements and format for registration applications
Regional harmonised guidelines & procedures: • Guidelines for
registration of medicines
• Procedures for evaluation of medicines
• GMP guidelines & Inspection procedures
• Joint evaluations and inspections
• Sharing assessment and inspection reports
• Quality Management Systems
• Information Management Systems
Centralized registration on behalf of participating member states
Regional Medicines Agencies e.g. EAC-MFSA
16
1. Harmonised requirements and standards
Not Harmonised Fully Harmonised
National sovereignty is respected: Medicines registration decisions remaining firmly that of sovereign nations
Robust & transparent regulatory processes
Critical Milestones
Working independently
Member States Collaborate on training programmes
Harmonised training standards and broad collaboration
Utilise Existing Regional structures & expertise: NMRAs & Academic institutions
Existing training programmes for NMRA staff based on donor funding
• Evaluation & registration of medicines
• GMP Inspections
• Quality Management Systems
• Management Information Systems
• Harmonised training curriculum
• Certification • Evaluation of
training programmes
• Potential partners: WHO, US-FDA, PQM, AfDB, EDCTP, ANDi, PDPs, SIAPS
Short Term:• Twinning/Exchange
programmes among NMRAs within & outside the continent
• Regional Centres of Regulatory Excellence (RCORE)
Long-Term:• Engagement of academic
institutions to offer post graduate courses in Regulatory Science
17
2. Regulatory capacity development
Ad-hoc training programmes Institutionalised training programmes
• Increased regulatory workforce in Africa
Critical Milestones
Current status Country level Regional level Continental level
• Lack/Weak medicines laws
• Medicines regulated within territories
• Varying comprehensiveness of laws
• No sanctions on non compliance to regional treaties
• Adoption and domestication of model law on medicines regulation
• Mutual recognition agreements
• Binding regional legal instruments
• At least 5 regions have adopted regionally harmonized policies and legislative frameworks
• At least 20 countries implementing the regionally harmonized policies and legislative frameworks
• At least 2 regional medicines agencies established
18
3. Policy and Regulatory Reforms
Inadequate policies & laws Harmonised policies & Laws
• Increased adoption of regionally agreed standards• Mutual recognition of regulatory decisions
• Establishment of regional medicines agencies
3. AMRH Achievements
19
1. GMRH Multi-Donor Trust Fund
• The World Bank administration of a Global Medicines Regulatory Harmonization Multi-Donor Trust Fund (GMRH-MDTF)
• Initial funds to cover EAC Medicines Registration Harmonization Project and AMRH Partners
• US$ 12.5 million• Bill & Melinda Gates Foundation provided initial start-up
grant while other interested donors are engaged
• Strategically mobilize resources to cover other RECs• Sustainable domestic financing options
2020
04/12/2023 21
2. CONTINENTAL PROGRESS
• AMRH Advisory Committee established – NEPAD Agency Secretariat: Coordination and Political advocacy– Provides strategic and policy advise on AMRH programme
implementation– Composed of representatives from RECs, NMRAs, AUC, PAP,
NEPAD, WHO, World Bank, industry associations, civil society
• Technical Working Groups– Regulatory Capacity Development– Medicines Policies & Regulatory Reforms
• Draft Model Law for Medicines Regulation Harmonization in Africa developed– Stakeholders consultations planned for 2013
CONTINENTAL PROGRESS…
Related Continental Frameworks• July 2012: 19th AU Assembly decision on Roadmap for
Shared Responsibility and Global solidarity for the AIDS, TB and Malaria response in Africa
– Emphasis - accelerate and strengthen regional medicines regulatory harmonization initiatives
– Establishment of regional medicines agencies– Foundation for a single African Regulatory Agency– Lead Partners: AUC, UNAIDS & NEPAD Agency
22
3. REGIONAL PROGRESSEast African Community• Launch & subsequent implementation of EAC Medicines Registration
Harmonization (MRH) Project since March 2012
• 5 EAC Partner States (6 NMRAs) participating in the AMRH Initiative: Burundi, Kenya, Rwanda, Tanzania, Uganda
• MRH Project Steering Committee Established
• Technical Working Groups (TWG) established to develop registration and GMP guidelines and procedures in line with internationally acceptable standards
• Partner States NMRAs taking lead• Tanzania: TWG on medicines evaluation & registration• Uganda: TWG on good manufacturing inspection• Kenya: TWG on quality management systems
• Rwanda: TWG on Information Management System (IMS) 2323
REGIONAL PROGRESS…
West African region:• 15 participating member states• 2011: Development of MRH Project framework in
consultation with industry• August – Nov 2012:
– WAHO, UEMOA, WHO & NEPAD Agency High Level consultation meetings
– Experts consultation meetings– WAHO engagement of 7 countries (5 Anglophone & 2 Lusophone)– UEMOA engagement of 8 Francophone countries
• 2013: WAHO/UEMOA Regional coordination framework, plan of action and Memorandum of Understanding
24
REGIONAL PROGRESS…
Central African region• 10 participating member states
• 2009-11: Situation analysis and development of a project framework for OCEAC/ECCAS
• 2012: Consultation with OCEAC and ECCAS
• 2013: Consultation on OCEAC/ECCAS Regional coordination framework, plan of action and memorandum of understanding
25
4. PHARMA INDUSTRY PARTICIPATION• 2010-2012: NEPAD commissioned situation
analysis of medicines regulation & harmonization across African RECs and countries– National & regional policy & legislative frameworks– NMRAs assessment
• 3 categories based on agreed criteria; i) Existing NMRA; ii) Existing legal framework; iii) performance of full regulatory functions (registration, GMP); iv) Existing Management Information System; v) Available HR
– Industry perception on AMRH• Consultation through National & regional industry associations• General agreement
• EAC, SADC, ECOWAS consultation meetings– Development of regional MRH Frameworks
26
AMRH Coverage Roughly 85% of Sub-Saharan Africa
27
RECsCountries covered
Population(Mill)
Pharma market
(US$ Bill p.a.)
EAC ECCAS/OCEACECOWAS-WAHO/UEMOASADCUMA/CEN-SADC/COMESA/IGAD
51015159
133.1120~300267.58N/A
N/AN/A3.5 (2010)3 (2006)N/A
Total: 54
REC Status/Progress
Source: BCG analysis
SADC
• We are pushing forward with RECs that are willing
• Industry participation in stakeholders consultation is key
• National & regional industry association a good platform for engagement
27
WAHO/UEMOAEAC
ECCAS/OCEAC
28
AMRH contribution to Pharma Industry Development dev
Intermediateterm
Long term
Increased access to generics treating many
important diseases
Broader, more rapid access to vaccines and
other therapies
Extension to all regulatory functions
More efficient launches for vaccines and
other PDP products
Greater impact of new life-saving technologies
Foundation for African pharma industry
(PMPA)
• Benefit to Regional Economic & Trade Treaties
• Increased market access
Healthier, more productive workforce
Short term
Prevention and treatment of infections diseases (overall)
Broad economic development in the
regionEnhanced access to
new health technologies
üü ü
ü
üü ü28
5. WAY FORWARD• Regional Stakeholders consultation
– EAC harmonised guidelines & procedures– AMRH Model Law
• Institutionalization of the regulatory training programmes in the continent– Establishment of Regional centres of regulatory Excellence
(RCOREs)– Training for regulators & industry– Key for sustainability
• Expanding the scope for harmonization to clinical trials oversight and safety monitoring
• Governance and effective coordination regionally & continentally– Establishment of Partnership Platform Accountability Framework– Impact assessment of policy & regulatory reforms in Africa
• Continued political advocacy
29
WAY FORWARD…• 1st Scientific conference for medicines regulation in
Africa– Theme:
“Building Partnerships for Sustainable Capacity Development in Medicines Regulation in Africa”
– Target group: African regulatory authorities, researchers, academic institutions and industry
• Necessity of working together to address socio-economic issues affecting the African populace
– Call for Abstracts
• Read: AMRH-PMPA Policy Brief• Visit: www.amrh.org
30
CONCLUSION• AMRH is a strategic initiative for pharmaceutical sector
development in Africa
• Strong political constituency and partnerships built– AU organs (AUC, NEPAD Agency, PAP), RECs, NMRAs,
pharmaceutical industry & Civil Society– Donors, development partners & international agencies
• Cooperation, collaboration and commitment by all stakeholders is key for success– Need practical alignments & engagement between African
NMRAs, industry, academia and researchers
• EAC MRH Project provides a Model for replication to other RECs
04/12/2023 31
Thank You!
Merci!
Obrigado!
Ahsanteni Sana!
32
Top Related